Lotta Agholme
Cellectricon ABGothenburg, Sweden
330988 RESULTS
Cellectricon ABGothenburg, Sweden
CONFERENCE COVERAGE 2012-11-21 Conference Coverage Stakeholders in the Alzheimer’s disease field often cite the tremendous burden the disease puts on the healthcare system—estimated at $600 billion annually worldwide (see World Alzheimer Report 2010 and ARF related news story)—as a com
CONFERENCE COVERAGE 2012-11-21 Conference Coverage Viewed through a scientist’s lens, professional boxing is a series of scheduled, measurable head traumas. In other words, it is a human model for chronic traumatic encephalopathy (CTE). Seen this way, the sport offers a unique opportun
RESEARCH NEWS 2012-11-21 Research News In a Phase 2 trial of Bristol-Myers Squibb’s oral γ-secretase inhibitor avagacestat, AD patients who took high doses suffered more adverse effects and appeared to fare worse cognitively than those on placebo. Christopher van Dyck of Yale Uni
CONFERENCE COVERAGE 2012-11-21 Conference Coverage Franklin’s genius notwithstanding, death and taxes are not the only things that are certain. It’s pretty clear you can’t evade your genetics, either. But what about epigenetics? While tweaking the tax code might improve your fortune, c
PAPER Bertoux M, Volle E, Funkiewiez A, de Souza LC, Leclercq D, Dubois B
PAPER Barandiaran M, Estanga A, Moreno F, Indakoetxea B, Alzualde A, Balluerka N, Martí Massó JF, de Munain AL
PAPER van Blitterswijk M, Dejesus-Hernandez M, Rademakers R
PAPER Goodwin J, Nath S, Engelborghs Y, Pountney DL
PAPER Narayanan C, Weinstock DS, Wu KP, Baum J, Levy RM
PAPER Thakur P, Nehru B
PAPER Liu J, Shen Y, Li M, Shi Q, Zhang A, Miao F, Wu X, He Y, Zhang J
PAPER Chamberland S, Topolnik L
PAPER Zhang G, Morin C, Zhu X, Bao Huynh M, Ouidir Ouidja M, Sepulveda-Diaz JE, Raisman-Vozari R, Li P, Papy-Garcia D
PAPER Wisniewska MB, Nagalski A, Dabrowski M, Misztal K, Kuznicki J
No filters selected